Benner added, Keating promoted at Astellas
NORTHBROOK - Astellas announced the appointment of Steven E. Benner as senior vice president and Therapeutic Area Head for Oncology, and the promotion of Anne Keating to vice president of Clinical Science for Oncology, within the company's development organization.
Benner and Keating will be located at Astellas' office in Northbrook.
In his new role, Benner will report to Zeiher and be responsible for providing global leadership for Astellas' Oncology therapeutic area, which includes numerous clinical programs in areas such as prostate cancer, leukemia, lung cancer and breast cancer, among others.
Benner previously served in senior leadership positions in clinical development, compliance and licensing at Cell Therapeutics Inc., OncoMed Pharmaceuticals, PDL BioPharma and Bristol-Myers Squibb, as well as academic appointments at the University of North Carolina - Chapel Hill School of Medicine and the University of Texas MD Anderson Cancer Center.
In her new role, Keating will be responsible for the vision, leadership and strategic direction for the execution of all phases of Astellas' Clinical Science oncology programs globally, applying operational best practices into the design and execution of projects across the company's portfolio in collaboration with Clinical Science colleagues around the world. Keating will report to Eric Terhaerdt, senior vice president, Development Operations.
Keating joined Astellas in 2004 as a director of clinical operations, and has held a series of roles of increasing responsibility. Most recently, she served as an executive director and global development project leader for oncology, overseeing the clinical development program for ASP8273, Astellas' investigative medicine for the treatment of non-small-cell lung cancer.